Information Disclosure Statement - June 16, 2010 Sheet 1 of ATTY. DOCKET NO. SERIAL NO. INFORMATION DISCLOSURE **CITATION** 620-454 10/591,847 **APPLICANT** HOFLAND et al. (Use several sheets if necessary) FILING DATE GROUP 1623 January 9, 2007 **U.S. PATENT DOCUMENTS** *EXAMINER FILING DATE INITIAL DOCUMENT NUMBER DATE NAME CLASS **SUBCLASS** IF APPROPRIATE FOREIGN PATENT DOCUMENTS TRANSLATION DOCUMENT DATE COUNTRY CLASS SUBCLASS NO OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.) Sehested et al, "ANTAGONISTIC EFFECT OF THE CARDIOPROTECTOR (+)-1,2-BIS(3,5-DIOXOPIPERAZINYL-1-YL)PROPANE (ICRF-187) ON DNA BREAKS AND /G.M¢YTOTOXICITY INDUCED BY THE TOPOISOMERASE II DIRECTED DRUGS DAUNORUBICIN AND ETOPOSIDE (VP-16)", Biochemical Pharmacology, Vol. 46, No. 3,

DIOXOPIPERAZINYL-1-YL)PROPANE (ICRF-187) ON DNA BREAKS AND CYTOTOXICITY INDUCED BY THE TOPOISOMERASE II DIRECTED DRUGS DAUNORUBICIN AND ETOPOSIDE (VP-16)", Biochemical Pharmacology, Vol. 46, No. 3, pp 389-393, 1993

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)